Inactive Instrument

ImmunoPrecise Antibodies Ltd. Stock Toronto S.E.

Equities

IPA

CA45257F2008

Pharmaceuticals

Sales 2024 * 24.59M 17.87M Sales 2025 * 29.82M 21.68M Capitalization 44.86M 32.61M
Net income 2024 * -12M -8.72M Net income 2025 * -9M -6.54M EV / Sales 2024 * 1.82 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.5 x
P/E ratio 2024 *
-3.53 x
P/E ratio 2025 *
-4.79 x
Employees 102
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.41%
More Fundamentals * Assessed data
Dynamic Chart
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments CI
Transcript : ImmunoPrecise Antibodies Ltd., Q3 2024 Earnings Call, Mar 14, 2024
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Certain Warrants of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024. CI
Certain Stock Options of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024. CI
Certain Common Shares of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024. CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Transcript : ImmunoPrecise Antibodies Ltd., Q2 2024 Earnings Call, Dec 14, 2023
Top Premarket Gainers MT
Private Payrolls Increased Less Than Expected in November as US Equity Futures Rise Pre-Bell MT
Jobs Data in Focus as Exchange-Traded Funds, Equity Futures Lean Higher Pre-Bell Wednesday MT
Top Premarket Decliners MT
ImmunoPrecise Antibodies Plans Underwritten Offering of Common Stock; Shares Fall Pre-Bell MT
ImmunoPrecise Antibodies Ltd. Announces Board Changes CI
ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology CI
More news
Managers TitleAgeSince
Chief Executive Officer - 18-02-20
Director of Finance/CFO - 23-09-28
Chief Tech/Sci/R&D Officer - 21-06-30
Members of the board TitleAgeSince
Chairman - -
Director/Board Member 59 23-09-04
Chief Executive Officer - 18-02-20
More insiders
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.
More about the company